Paratek Pharmaceuticals Announced That The European Medicines Agency Committee For Orphan Medicinal Products Has Recommended Positive Opinion For Orphan Medicinal Product Designation For Nuzyra (Omadacycline) For Nontuberculous Mycobacterial Lung Disease
Portfolio Pulse from Benzinga Newsdesk
Paratek Pharmaceuticals announced that the European Medicines Agency Committee for Orphan Medicinal Products has recommended a positive opinion for orphan medicinal product designation for Nuzyra (Omadacycline) for nontuberculous mycobacterial lung disease.
June 27, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Paratek Pharmaceuticals' Nuzyra receives a positive opinion for orphan medicinal product designation, potentially opening up a new market for the drug.
The positive opinion for Nuzyra's orphan medicinal product designation indicates that the drug may be approved for use in treating nontuberculous mycobacterial lung disease. This could open up a new market for Paratek Pharmaceuticals, potentially increasing its revenues and positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100